BR112014011262A2 - carboxamida com base em pirazolila substituída e derivados de ureia que portam uma porção de fenila substituída com um grupo contendo o como ligantes de receptor vaniloide - Google Patents

carboxamida com base em pirazolila substituída e derivados de ureia que portam uma porção de fenila substituída com um grupo contendo o como ligantes de receptor vaniloide

Info

Publication number
BR112014011262A2
BR112014011262A2 BR112014011262A BR112014011262A BR112014011262A2 BR 112014011262 A2 BR112014011262 A2 BR 112014011262A2 BR 112014011262 A BR112014011262 A BR 112014011262A BR 112014011262 A BR112014011262 A BR 112014011262A BR 112014011262 A2 BR112014011262 A2 BR 112014011262A2
Authority
BR
Brazil
Prior art keywords
substituted
group containing
phenyl moiety
urea derivatives
vanyl
Prior art date
Application number
BR112014011262A
Other languages
English (en)
Other versions
BR112014011262A8 (pt
BR112014011262B1 (pt
Inventor
Lesch Bernhard
John Saunders Derek
Bahrenberg Gregor
Stockhausen Hannelore
De Vry Jean
Lee Jeewoo
Schiene Klaus
Kim Myeong-Seop
Damann Nils
Frank-Foltyn Robert
Christoph Thomas
Kim Yong-Soo
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of BR112014011262A2 publication Critical patent/BR112014011262A2/pt
Publication of BR112014011262A8 publication Critical patent/BR112014011262A8/pt
Publication of BR112014011262B1 publication Critical patent/BR112014011262B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

resumo patente de invenção: "carboxamida com base em pirazolila substituída e derivados de ureia que portam uma porção de fenila substituída com um grupo contendo o como ligantes de receptor vaniloide". a presente invenção refere-se a carboxamida com base em pirazolila substituída e derivados de ureia que portam uma porção de fenila substituída com um grupo contendo o como ligantes de receptor vaniloide, a composições farmacêuticas contendo esses compostos e também a esses compostos para o uso no tratamento e/ou profilaxia de dor e outras doenças e/ou desordens.
BR112014011262-2A 2011-11-09 2012-11-08 Carboxamidas à base de pirazolila substituída e derivados de ureia, seu uso, e composição farmacêutica BR112014011262B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11008914.1 2011-11-09
EP11008914 2011-11-09
PCT/EP2012/072140 WO2013068461A1 (en) 2011-11-09 2012-11-08 Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an o-containing group as vanilloid receptor ligands

Publications (3)

Publication Number Publication Date
BR112014011262A2 true BR112014011262A2 (pt) 2017-04-25
BR112014011262A8 BR112014011262A8 (pt) 2018-03-06
BR112014011262B1 BR112014011262B1 (pt) 2022-02-15

Family

ID=47143122

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014011262-2A BR112014011262B1 (pt) 2011-11-09 2012-11-08 Carboxamidas à base de pirazolila substituída e derivados de ureia, seu uso, e composição farmacêutica

Country Status (14)

Country Link
EP (1) EP2776398B1 (pt)
JP (1) JP6189313B2 (pt)
KR (1) KR101985442B1 (pt)
CN (2) CN107739338A (pt)
AR (1) AR088702A1 (pt)
AU (1) AU2012334065B2 (pt)
BR (1) BR112014011262B1 (pt)
CA (1) CA2854932A1 (pt)
ES (1) ES2823577T3 (pt)
HK (1) HK1201839A1 (pt)
IN (1) IN2014KN00849A (pt)
MX (1) MX2014005610A (pt)
TW (1) TW201326133A (pt)
WO (1) WO2013068461A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016096140A1 (en) * 2014-12-19 2016-06-23 Grünenthal GmbH Process for the preparation of 1-[(heteroaryl)-methyl]- or 1-[(aryl)-methyl]-3-[4-(hydroxymethyl)-phenyl]-ureas
CA3019281A1 (en) * 2016-03-31 2017-10-05 Toyama Chemical Co., Ltd. Novel method for producing hydroxamic acid derivative and intermediate therefor
CN113135856B (zh) * 2021-04-08 2022-10-11 天津大学 一类3-三氟甲基-5-氰基吡唑化合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012910A1 (fr) * 1997-09-11 1999-03-18 Nissan Chemical Industries, Ltd. Composes a base de pyrazole et agent de lutte contre les maladies vegetales
US7767670B2 (en) * 2003-11-13 2010-08-03 Ambit Biosciences Corporation Substituted 3-carboxamido isoxazoles as kinase modulators
JP2005314407A (ja) * 2004-03-31 2005-11-10 Nippon Nohyaku Co Ltd 新規なハロアルキルスルホンアニリド誘導体、除草剤及びその使用方法並びにその中間体
PT1940821E (pt) * 2005-10-19 2013-05-29 Gruenenthal Gmbh Novos ligandos do receptor de vanilóide e seu uso para a produção de medicamentos
US7998995B2 (en) * 2006-12-08 2011-08-16 Exelixis Patent Company Llc LXR and FXR modulators
DE102007018151A1 (de) * 2007-04-16 2008-10-23 Günenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
PT2427436E (pt) * 2009-05-07 2013-03-04 Gruenenthal Gmbh Derivados aromáticos substituídos de carboxamida e ureia como ligantes de receptor de vanilóide
TWI491595B (zh) * 2009-05-07 2015-07-11 歌林達股份有限公司 作為香草類化合物受體之配體之經取代苯基尿素及苯基醯胺
AU2011223790A1 (en) * 2010-03-01 2012-08-30 Myrexis, Inc. Compounds and therapeutic uses thereof

Also Published As

Publication number Publication date
KR20140091043A (ko) 2014-07-18
EP2776398B1 (en) 2020-09-02
TW201326133A (zh) 2013-07-01
AU2012334065A1 (en) 2014-05-22
KR101985442B1 (ko) 2019-06-03
MX2014005610A (es) 2014-07-30
EP2776398A1 (en) 2014-09-17
HK1201839A1 (en) 2015-09-11
CA2854932A1 (en) 2013-05-16
JP2014532741A (ja) 2014-12-08
CN103889961A (zh) 2014-06-25
CN107739338A (zh) 2018-02-27
IN2014KN00849A (pt) 2015-10-02
ES2823577T3 (es) 2021-05-07
BR112014011262A8 (pt) 2018-03-06
JP6189313B2 (ja) 2017-08-30
WO2013068461A1 (en) 2013-05-16
AU2012334065B2 (en) 2017-06-08
BR112014011262B1 (pt) 2022-02-15
AR088702A1 (es) 2014-06-25

Similar Documents

Publication Publication Date Title
BR112014001880A2 (pt) derivados de carboxamida e ureia contendo pirazol heteroaromáticos substituídos como ligantes de receptor vaniloide
BR112014001908A2 (pt) derivados aza heterocíclicos substituídos
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112013027670A2 (pt) "composto de amida, composição farmacêutica e medicamento que o compreende e antagonista de rory"
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
BR112015029090A8 (pt) 3,4-dihidroisoquinolin- 2(1h)-ila, seus usos, composição farmacêuticas e sua forma cocristalina
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
BR112013026807A2 (pt) derivados de metil amina bicíclicos substituídos como moduladores dos receptores de esfinfgosina-1 fosfato
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
EA201590562A1 (ru) Бензамиды
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
UY33568A (es) Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes.
BR112014001714A2 (pt) derivados de carboxamida e ureia aromáticos bicíclicos substituídos como ligantes de receptor vaniloide
BR112014006675A2 (pt) derivados de metanossulfonamida substituídos como ligantes de receptor vaniloide
BR112014011262A2 (pt) carboxamida com base em pirazolila substituída e derivados de ureia que portam uma porção de fenila substituída com um grupo contendo o como ligantes de receptor vaniloide
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
BR112014006788A2 (pt) derivados de metanossulfonamida substituídos com arila ou n-heteroarila como ligantes de receptor vaniloide
BR112014011108A2 (pt) derivados de carboxamida e ureia à base de pirazolila substituída portando uma porção fenila substituída com um grupo contendo so2 como ligantes do receptor de vaniloides
BR112014016450A2 (pt) composto antagonista de leucotrieno b4

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MEDIFRON DBT INC. (KR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/11/2012, OBSERVADAS AS CONDICOES LEGAIS.